Figure 6From: Deglycosylation and label-free quantitative LC-MALDI MS applied to efficient serum biomarker discovery of lung cancer Immunoblot verification of complement C3dg serum levels in the study subjects. (A) Detection of 39 kDa C3dg fragment from 0.02 μL of crude serum using anti-C3 antibody. Lanes represent 10 subjects each of normal control, early stage lung cancer (stage-I/II) and advanced stage lung cancer (stage-IIIb/IV). (B) Dot plot of the data shown in (A), quantified as the ratio of C3dg detection level to the normalization lane M, a 40 kDa size marker that has cross-reactivity with the secondary antibody.Back to article page